On this page
Back to topBlossomHill Therapeutics BLSM
BlossomHill Therapeutics listed on Nasdaq on 7 Aug 2026 and is not in the S&P 500. It is worth $458 million. Its price history starts on 7 Aug 2026. 7 directors have filed with the SEC in the last 12 months (who counts), 2 of them executives. 3 other officers are on file.
- CEO
- Jingrong Jean Cui
- Chair
- Yishan Li
- Listed
- 7 Aug 2026 on Nasdaq, IPO filings and terms
- Headquarters
- San Diego, CA
- Market cap
- $458M
- 19 Nov 2026 close
- Revenue
- -
- No annual report yet
Financials
BlossomHill Therapeutics' market cap since August 2026
Weekly, up to 13 Nov 2026
| Week ending | Market cap |
|---|---|
| 13 Nov 2026 | $450M |
Download BlossomHill Therapeutics' data as JSON, with the weekly market caps in billions of dollars from 7 Aug 2026.
Board and leadership
Board and officers
Roles filed up to 30 Sep 2026
| Name | Title |
|---|---|
| Directors (7) | |
| Yishan LiExecutive Chairman | |
| Jingrong Jean CuiPresident and CEO | |
| Sundeep AgrawalDirector | |
| Bihua ChenDirector | |
| Carl L. GordonDirector | |
| Sheila GujrathiDirector | |
| John P. SchmidDirector | |
| Officers (3) | |
| Jason A. KeyesChief Financial OfficerLast filed 10 Aug 2026 | |
| Vincent Paul LiptakGeneral CounselLast filed 10 Aug 2026 | |
| Geoffrey Raymond OxnardChief Medical OfficerLast filed 10 Aug 2026 | |
Owners and trading
Insider trades
Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.
Trades from 19 Nov 2025 to 19 Nov 2026
Directors and officers made no open-market sales and bought $15.2 million in 6 purchases in the 12 months to 19 Nov 2026.
| Date | Person | Value |
|---|---|---|
| 10 Aug 2026Buy | Carl L. GordonDirector | $10M |
| 10 Aug 2026Buy | Bihua ChenDirector | $5.0M |
| 10 Aug 2026Buy | John P. SchmidDirector | $96K |
| 10 Aug 2026Buy | Vincent Paul LiptakGeneral Counsel | $35K |
| 10 Aug 2026Buy | Jason A. KeyesChief Financial Officer | $11K |
| 7 Aug 2026Buy | Vincent Paul LiptakGeneral Counsel | $40K |
Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months, no quarterly results in its SEC XBRL filings and no director or officer changes, WARN notices or large insider sales in the last two years. 13F holdings: BlossomHill Therapeutics listed after the last quarter (30 Jun 2026). The next 13F filings were due by 14 Nov 2026.